LifeCell
This article was originally published in The Gray Sheet
Executive Summary
Raises $3.4 mil. from the exercise of 97.6% of its outstanding warrants by warrant holders; the firm redeemed the remaining 2.4% of outstanding warrants ("The Gray Sheet" Dec. 21, 1992, p. 16). LifeCell will use a portion of the funds for commercialization of AlloDerm, its processed dermal skin replacement tissue. AlloDerm is being studied in a six-center trial for the treatment of full-thickness burns ("The Gray Sheet" Feb. 3, 1992, I&W-15); the firm expects to begin commercializing the product this year. Proceeds from the redemption also will be used to accelerate LifeCell's "product development programs in tissue replacements and transfusable blood cells".